ABSTRACT
Neoadjuvant chemotherapy or neoadjuvant chemotherapy in combination with targeted therapy has been widely accepted as the standard treatment for locally advanced breast cancer (Ⅱb-Ⅲ). Nearly forty percent of the patients who accepted neoadjuvant chemotherapy achieved pathological complete response of axillary lymph nodes in addition to downstage the primary lesions. However, for patients with clinical complete response of lymph nodes after pre-operative systemic therapy, there are constant controversies regarding the prediction of axillary lymph nodes response and sentinel lymph nodes biopsy after the treatment. Here we design to review the latest studies about how to evaluate the axillary lymph nodes response after neoadjuvant chemotherapy and try to enlighten the treatment choices in clinical practice.
ABSTRACT
Objective To evaluate the sentinel lymph node biopsy (SLNB) in clinical lymph node negative oral squamous cell carcinoma. Methods Sentinel lymph node biopsy (SLNB) by using methylene blue staining were employed to 20 patients with clinical cervical lymph node negative in oral squamous cell carcinoma. Results SLNB was successful identified in 14 of 20(70%). A 100%(6/6) accuracy of SLNB to predict cervical lymph node status was reached. Conclusion SLNB could accurately predict the cervical status of clinical negative node and decrease the extent of surgery and postoperative complication